Browsing by Author "Pekel, Gonca"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Anticancer potential of albumin bound wnt/β-catenin pathway inhibitor niclosamide in breast cancer cells
    (Wiley-v C H Verlag Gmbh, 2021-08-06) Ari, Ferda; Erkisa, Merve; Pekel, Gonca; Buyukkoroglu, Gulay; Ulukaya, Engin; Erturk, Elif; ERTÜRK, ELİF; Arı, Ferda; Erkısa, Merve; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Sağlık Hizmetleri Meslek Yüksekokulu.; 0000-0002-6729-7908; 0000-0002-3127-742X; 0000-0002-5089-6007; 0000-0003-4875-5472; K-5792-2018; N-6551-2019; JQI-3400-2023; AAM-1001-2020; IWM-5784-2023
    Albumin-based nanoparticle transport systems (nab-technology) are a new strategy in cancer treatment and we aimed to increase the effectiveness of Niclosamide using this technology. Niclosamide was bound with bovine serum albumin (BSA) by desolvation to yield nanoparticle albumin-bound Niclosamide (nab-Niclo). Nab-Niclo anticancer activity was assessed by proliferation, apoptosis and DNA damage analyses on breast cancer cells. The results implied that nab-Niclo was a more potent agent in the inhibition of cell viability than free Niclosamide and albumin. Flow cytometry analysis show that nab-Niclo triggered apoptosis by caspase and mitochondriadependent pathways in cells and nab-Niclo enhances apoptosis by induce DNA damage in cells. Overall results of this study showed that the nanoparticle form of Niclosamide is effective for breast cancer treatment, presenting a new treatment strategy that can be safe and effective for breast cancer patients.
  • No Thumbnail Available
    Item
    Therapeutic targeting of cancer metabolism with triosephosphate isomerase
    (Wiley, 2020-03-16) Pekel, Gonca; Arı, Ferda; Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.; 0000-0002-6729-7908; 0000-0003-2567-8056; 57216587784; 24376085300
    The increase in glycolytic flux in cancer, known as aerobic glycolysis, is one of the most important hallmarks of cancer. Therefore, glycolytic enzymes have importance in understanding the molecular mechanism of cancer progression. Triosephosphate isomerase (TPI) is one of the key glycolytic enzymes. Furthermore, it takes a part in gluconeogenesis, pentose phosphate pathway and fatty acid biosynthesis. To date, it has been shown altered levels of TPI in various cancer types, especially in metastatic phenotype. According to other studies, TPI might be considered as a potential therapeutic target and a cancer-related biomarker in different types of cancer. However, its function in tumor formation and development has not been fully understood. Here, we reviewed the relationship between TPI and cancer for the first time.